BioCancell Share Price Rises Following Successful Phase II Trials

September 28, 2014 | BioCancell Therapeutics, an Israeli company researching and developing cancer drugs, announced a successful clinical trial of its treatment on high-risk bladder cancer patients. The US Food & Drug Administration, which requires that the trial be conducted successfully in order to move on to Phase III, will allow the company’s BC-819 drug, which is used together with existing bladder cancer treatment BCG, to move forward in the approval process. As a result, the company’s share price rose by nine percent in afternoon trading on Tuesday on the TASE. In the trail, 17 high-risk bladder cancer patients, whom already had malignant tumors removed, were treated with a mix of BC-819 and BCG three times a day, and 11 of the patients saw no reoccurence of malignant tumors up to three months from the beginning of treatment. BioCancell was founded in 2004 by Hebrew University Professor Avraham Hochberg and is based on a technology developed by him over the past 20 years.